Catalyst Event

AbbVie Inc (ABBV) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/12/2026, 12:00:00 AM

OtherSentiment: Positive

AbbVie is expected to present final nine-year results from the Phase 3 CLL14 trial at the EHA 2026 Congress; doubling median progression-free survival is estimated to have a >10% price impact, expected.

Korean Translation

AbbVie가 유럽혈액학회 2026에서 3상 CLL14 임상 최종 결과를 발표할 예정이며, 무진행 생존기간 두 배 연장 성과는 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline